Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：50

作者：

Bannerji, Rajat ^{[1
]}

Allan, John N. ^{[2
]}

Arnason, Jon E. ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Advani, Ranjana H. ^{[5
]}

Barnes, Jeffrey A. ^{[6
]}

Ansell, Stephen M. ^{[7
]}

O'Brien, Susan M. ^{[8
]}

Chavez, Julio ^{[9
]}

Duell, Johannes ^{[10
]}

David, Kevin A. ^{[1
]}

Martin, Peter ^{[11
]}

Joyce, Robin M. ^{[3
]}

Charnas, Robert ^{[12
]}

Ambati, Srikanth R. ^{[12
]}

Adriaens, Lieve ^{[12
]}

Ufkin, Melanie ^{[12
]}

Zhu, Min ^{[12
]}

Li, Jingjin ^{[12
]}

Gasparini, Peter ^{[12
]}

Ibrahim, Anfal ^{[12
]}

Jankovic, Vladimir ^{[12
]}

Fiaschi, Nathalie ^{[12
]}

Aina, Olulanu ^{[12
]}

Zhang, Wen ^{[12
]}

Deering, Raquel P. ^{[12
]}

Hamon, Sara ^{[12
]}

Thurston, Gavin ^{[12
]}

Murphy, Andrew J. ^{[12
]}

Weinreich, David M. ^{[12
]}

Yancopoulos, George D. ^{[12
]}

Lowy, Israel ^{[12
]}

Sternberg, David ^{[12
]}

Topp, Max S. ^{[13
]}

机构：

[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[2] Weill Cornell Med, Long Isl City, NY USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[5] Stanford Univ, Stanford, CA 94305 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Mayo Clin, Rochester, MN USA

[8] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Klinikum Wurzburg, Wurzburg, Germany

[11] Weill Cornell Med, New York, NY USA

[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[13] Univ Wurzburg, Wurzburg, Germany

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122451

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

762

引用

页数：8

共 50 条

[11] Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
Topp, Max S.
Borchmann, Peter
Wagner-Johnston, Nina D.
Provencio, Mariano
Cordoba, Raul
Papadopoulos, Kyriakos
Martin, Alejandro
Grande, Carlos
Jagadeesh, Deepa
Lakhani, Nehal
de Vos, Sven
Mato, Anthony R.
Brunnberg, Uta
Scholl, Sebastian
Pott, Christiane
Rutherford, Sarah C.
Duell, Johannes
Adriaens, Lieve
Ufkin, Melanie
Kostic, Ana
Paccaly, Anne Josee
Gao, Bo
Lowy, Israel
Sternberg, David
Carpio, Cecilia
BLOOD, 2017, 130
[12] Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma
Patel, Krish
Michot, Jean-Marie
Chanan-Khan, Asher
Ghesquieres, Herve
Bouabdallah, Kamal
Byrd, John C.
Cartron, Guillaume
Portell, Craig A.
Solh, Melhem
Tilly, Herve
Wierda, William G.
McGovern, Patricia
Johnson, Chelsea
Garcha, Raman
Ribrag, Vincent
Brisou, Gabriel
Liebowitz, David
Phillips, Tycel
BLOOD, 2021, 138
[13] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Christian, Beth A.
Poi, Ming
Jones, Jeffrey A.
Porcu, Pierluigi
Maddocks, Kami
Flynn, Joseph M.
Benson, Don M.
Phelps, Mitch A.
Wei, Lai
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
[14] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Bannerji, Rajat
Allan, John N.
Arnason, Jon E.
Brown, Jennifer R.
Advani, Ranjana
Ansell, Stephen M.
O'Brien, Susan M.
Duell, Johannes
Martin, Peter
Joyce, Robin M.
Li, Jingjin
Flink, Dina M.
Zhu, Min
Weinreich, David M.
Yancopoulos, George D.
Sirulnik, Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Topp, Max S.
BLOOD, 2020, 136
[15] Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
Fanale, Michelle A.
Hamlin, Paul A.
Park, Steven I.
Persky, Daniel Oscar
Higgins, Jack P.
Burnett, Christine
Dabovic, Kristina
Poma, Eric
Sarapa, Nenad
Younes, Anas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[16] Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
Tobinai, Kensei
Ogura, Michinori
Maruyama, Dai
Suzuki, Tatsuya
Kobayashi, Yukio
Uchida, Toshiki
Fukuhara, Suguru
Oyama, Takashi
Fukuzaki, Tomoharu
Komatsu, Yasuhiko
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[17] Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Patel, Krish
Michot, Jean-Marie
Chanan-Khan, Asher A.
Salles, Gilles A.
Cartron, Guillaume
Peyrade, Frederic
Bouabdallah, Reda
Reid, Erin G.
Thomas, Sheeba K.
Wierda, William G.
Liebowitz, David
Pagel, John M.
Ribrag, Vincent
Saville, M. Wayne
Johnson, Chelsea M.
Ly, Thomas
Phillips, Tycel J.
BLOOD, 2019, 134
[18] Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab
Shahid, Zainab
Okwali, Michelle
Joseph, Ashlee
Seo, Susan K.
Lue, Jennifer Kimberly
Boardman, Alexander P.
Caron, Philip
David, Kevin A.
Epstein-Peterson, Zachary D.
Ghione, Paola
Hamlin, Paul A.
Horwitz, Steven M.
Intlekofer, Andrew M.
Johnson, William
Kumar, Anita
Moskowitz, Alison
Noy, Ariela
Owens, Colette
Palomba, Maria Lia
Stuver, Robert
Torka, Pallawi
Vardhana, Santosha A.
Zelenetz, Andrew D.
Salles, Gilles
Falchi, Lorenzo
BLOOD, 2023, 142
[19] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
Bender, Brendan C.
Li, Chi-Chung
Marchand, Mathilde
Turner, David C.
Li, Feifei
Vadhavkar, Shweta
Wang, Bei
Deng, Rong
Lu, James
Jin, Jin
Li, Chunze
Yin, Shen
Wei, Michael C.
Chanu, Pascal
BLOOD, 2023, 142
[20] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
Neumann, F
Martin, S
Kronenwett, R
Fischer, C
Kondakci, M
Kobbe, G
Gattermann, N
Haas, R
BLOOD, 2003, 102 (11) : 298B - 298B

← 1 2 3 4 5 →